AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24217302 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 20
Study 24217302 — intervention group
Group type: COMPARATOR
Intervention: Control (no levosimendan)
Number of subjects: 20
Study 21402120 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine (open label) for 6 weeks after initial treatment
Number of subjects: 0
Study 21402120 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine (12 weeks)
Number of subjects: 0
Study 21402120 — intervention group
Group type: COMPARATOR
Intervention: Placebo (initial treatment)
Number of subjects: 0
Study 18192497 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregiver intervention (not specified in detail)
Number of subjects: 182
Study 23120348 — intervention group
Group type: EXPERIMENTAL
Intervention: CT‐RT arm (neo‐adjuvant chemotherapy with Inj. Cisplatin 100 mg/m(2) on D(1) and Inj 5F.U. 700 mg/m(2) on D(1)‐D(4) at an interval of 21 days, followed by external radiation)
Number of subjects: 180
Study 23120348 — intervention group
Group type: COMPARATOR
Intervention: RT arm (external radiotherapy only)
Number of subjects: 180
Study 12210641 — intervention group
Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy (IPT)
Number of subjects: 62
Study 12210641 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication management
Number of subjects: 62
Study 12210641 — intervention group
Group type: COMPARATOR
Intervention: Control group (CBT)
Number of subjects: 62
Study 9604408 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized psychiatric assessment by a practice nurse and feedback to the GP (Study 1)
Number of subjects: 577
Study 9604408 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized psychiatric assessment by a practice nurse, feedback to the GP, and nurse-assisted follow-up care (Study 2)
Number of subjects: 577
Study 9604408 — intervention group
Group type: COMPARATOR
Intervention: Nurse intervention groups (combined from Study 1 and Study 2)
Number of subjects: 577
Study 7781842 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with macular oedema
Number of subjects: 20
Study 7781842 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study 2355104 — intervention group
Group type: EXPERIMENTAL
Intervention: Penbutolol 40 mg once daily (increased to 80 mg for poor responders)
Number of subjects: 50
Study 2355104 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 343414 — intervention group
Group type: EXPERIMENTAL
Intervention: mepindolol-sulfate
Number of subjects: 7
Study 343414 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 7
Study 29264969 — intervention group
Group type: EXPERIMENTAL
Intervention: Fermented soymilk (FSM) with Lactobacillus casei Shirota
Number of subjects: 60
Study 29264969 — intervention group
Group type: COMPARATOR
Intervention: Soymilk (SM) without isoflavones or probiotics
Number of subjects: 60
Study 26265197 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical diclofenac epolamine 1.3% patch
Number of subjects: 12
Study 26265197 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral diclofenac 50 mg
Number of subjects: 12
Study 26265197 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 325 mg
Number of subjects: 12
Study 26265197 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac potassium 50 mg
Number of subjects: 12
Study 26265197 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac potassium plus ASA 325 mg
Number of subjects: 12
Study 26265197 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac patch plus aspirin
Number of subjects: 12
Study 24879050 — intervention group
Group type: EXPERIMENTAL
Intervention: Larger provider groups
Number of subjects: 3100000
Study 24879050 — intervention group
Group type: COMPARATOR
Intervention: Smaller provider groups
Number of subjects: 3100000
Study 22366843 — intervention group
Group type: EXPERIMENTAL
Intervention: US-guided popliteal sciatic block (US-SPB) with 20 mL mepivacaine 1.5%
Number of subjects: 52
Study 22366843 — intervention group
Group type: COMPARATOR
Intervention: Nerve stimulator-guided popliteal sciatic block (NS-SPB) with 20 mL mepivacaine 1.5%
Number of subjects: 52
Study 22366843 — intervention group
Group type: EXPERIMENTAL
Intervention: US-guided popliteal sciatic block (US-SPB)
Number of subjects: 52
Study 22366843 — intervention group
Group type: COMPARATOR
Intervention: Nerve stimulator-guided popliteal sciatic block (NS-SPB)
Number of subjects: 52
Study 20060945 — intervention group
Group type: EXPERIMENTAL
Intervention: IC41 vaccine via subcutaneous (s.c.) or intradermal (i.d.) injections weekly (16 injections) or every other week (8 injections)
Number of subjects: 54
Study 20060945 — intervention group
Group type: EXPERIMENTAL
Intervention: IC41 vaccine with imiquimod
Number of subjects: 54
Study 20060945 — intervention group
Group type: EXPERIMENTAL
Intervention: IC41 vaccine via intradermal injections
Number of subjects: 54
Study 20060945 — intervention group
Group type: EXPERIMENTAL
Intervention: IC41 vaccine
Number of subjects: 54
Study 17358100 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin detemir
Number of subjects: 900
Study 17358100 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 900
Study 15730512 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ)
Number of subjects: 351
Study 15730512 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine (AQ)
Number of subjects: 351
Study 15730512 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphadoxine-pyrimethamine (SP)
Number of subjects: 351
Study 12049534 — intervention group
Group type: EXPERIMENTAL
Intervention: Nissen fundoplication with posterior cruroplasty
Number of subjects: 72
Study 12049534 — intervention group
Group type: COMPARATOR
Intervention: Nissen fundoplication with posterior cruroplasty and onlay of polytetrafluoroethylene (PTFE) mesh
Number of subjects: 72
Study 10357691 — intervention group
Group type: EXPERIMENTAL
Intervention: Tunneled femoral catheter
Number of subjects: 345
Study 10357691 — intervention group
Group type: COMPARATOR
Intervention: Nontunneled femoral catheter (Control)
Number of subjects: 345
Study 7607970 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy (RT) plus steroids
Number of subjects: 275
Study 7607970 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy (RT) alone
Number of subjects: 275
Study 1977179 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (2.25-9.0 micrograms/kg)
Number of subjects: 9
Study 1977179 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam (7.5-45 micrograms/kg)
Number of subjects: 9
Study 1977179 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 623119 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminum hydroxide (6 g daily, three times a day)
Number of subjects: 8
Study 623119 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminum hydroxide capsules
Number of subjects: 8
Study 30905872 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone app
Number of subjects: 80
Study 30905872 — intervention group
Group type: COMPARATOR
Intervention: Logbook
Number of subjects: 80
Study 28445286 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (Group R)
Number of subjects: 90
Study 28445286 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group C)
Number of subjects: 90
Study 25318368 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy (LA)
Number of subjects: 114
Study 25318368 — intervention group
Group type: COMPARATOR
Intervention: Open appendectomy (OA)
Number of subjects: 114
Study 24352716 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion (≤300 mg/day)
Number of subjects: 999
Study 24352716 — intervention group
Group type: COMPARATOR
Intervention: SSRIs (sertraline, paroxetine, or escitalopram)
Number of subjects: 999
Study 23021641 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertebroplasty for fracture age of 12 weeks or less
Number of subjects: 256
Study 23021641 — intervention group
Group type: COMPARATOR
Intervention: Vertebroplasty for fracture age greater than 12 weeks
Number of subjects: 256
Study 23021641 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertebroplasty for fracture age of 6 weeks or less
Number of subjects: 256
Study 23021641 — intervention group
Group type: COMPARATOR
Intervention: Vertebroplasty for fracture age greater than 6 weeks
Number of subjects: 256
Study 18927130 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% O(2) environment
Number of subjects: 230
Study 18927130 — intervention group
Group type: COMPARATOR
Intervention: 21% O(2) (atmospheric) environment
Number of subjects: 230
Study 17397743 — intervention group
Group type: EXPERIMENTAL
Intervention: Valdecoxib (Bextra), administered systemically
Number of subjects: 10
Study 15200450 — intervention group
Group type: EXPERIMENTAL
Intervention: pH neutral, lactate‐buffered, low GDP fluid (balance)
Number of subjects: 86
Study 15200450 — intervention group
Group type: COMPARATOR
Intervention: Conventional, acidic, lactate‐buffered fluid (SPDF)
Number of subjects: 86
Study 12074777 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 6g of L-arginine glutamate and 6 mg of yohimbine hydrochloride (AY)
Number of subjects: 45
Study 12074777 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg of yohimbine hydrochloride (YP)
Number of subjects: 45
Study 12074777 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PP)
Number of subjects: 45
Study 9718596 — intervention group
Group type: EXPERIMENTAL
Intervention: Tryptophan depletion
Number of subjects: 0
Study 9718596 — intervention group
Group type: COMPARATOR
Intervention: Balanced amino acid mixtures
Number of subjects: 0
Study 1986031 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine 3.0 micrograms/kg
Number of subjects: 8
Study 1986031 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine 6.0 micrograms/kg
Number of subjects: 8
Study 1986031 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 1986031 — intervention group
Group type: EXPERIMENTAL
Intervention: Scopolamine 3.0 micrograms/kg and 6.0 micrograms/kg
Number of subjects: 8
Study 6342395 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal magnesium sulfate infusion
Number of subjects: 0
Study 6342395 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 0
Study 31784875 — intervention group
Group type: COMPARATOR
Intervention: Dimethyl fumarate (Tecfidera®), administered twice daily.
Number of subjects: 0
Study 30193081 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic enzyme replacement therapy (PERT) at maximum intake of 75,000 units per meal
Number of subjects: 10
Study 30193081 — intervention group
Group type: COMPARATOR
Intervention: No PERT treatment
Number of subjects: 10
Study 26520703 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent androgen deprivation (IAD) with leuprorelin acetate (Eligard) 22.5mg 3‐mo depot for 36 months
Number of subjects: 933
Study 26520703 — intervention group
Group type: COMPARATOR
Intervention: Continuous androgen deprivation (CAD) with leuprorelin acetate (Eligard) 22.5mg 3‐mo depot for 36 months
Number of subjects: 933
Study 25204479 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone alone (P; N = 23)
Number of subjects: 87
Study 25204479 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone and azathioprine (P/A; N = 23)
Number of subjects: 87
Study 25204479 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone and mycophenolate mofetil (P/M; N = 21)
Number of subjects: 87
Study 25204479 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone and cyclophosphamide (P/C; N = 20)
Number of subjects: 87
Study 22500015 — intervention group
Group type: EXPERIMENTAL
Intervention: Incredible Years Teacher Training intervention
Number of subjects: 225
Study 22500015 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 225
Study 19779382 — intervention group
Group type: EXPERIMENTAL
Intervention: BZA 20 mg/CE 0.625 mg
Number of subjects: 664
Study 19779382 — intervention group
Group type: EXPERIMENTAL
Intervention: BZA 20 mg/CE 0.45 mg
Number of subjects: 664
Study 19779382 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 664
Study 18799988 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric diet with treadmill walking (low- or high-intensity)
Number of subjects: 34
Study 18799988 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypocaloric diet without treadmill walking
Number of subjects: 34
Study 18799988 — intervention group
Group type: COMPARATOR
Intervention: Weight regain
Number of subjects: 34
Study 16001926 — intervention group
Group type: EXPERIMENTAL
Intervention: Bottle-feeding
Number of subjects: 45
Study 16001926 — intervention group
Group type: COMPARATOR
Intervention: Spoon-feeding
Number of subjects: 45
Study 14517784 — intervention group
Group type: EXPERIMENTAL
Intervention: Hiatus Hernia (HH) patients
Number of subjects: 23
Study 14517784 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-Hernia (NHH) patients
Number of subjects: 23
Study 14517784 — intervention group
Group type: COMPARATOR
Intervention: Normal subjects (NL)
Number of subjects: 23
Study 10809945 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolon (replacement therapy)
Number of subjects: 54
Study 10809945 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 54
Study 10809945 — intervention group
Group type: COMPARATOR
Intervention: Before treatment
Number of subjects: 54
Study 9345074 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 weeks of induction chemotherapy (vincristine, doxorubicin, cyclophosphamide, prednisone) followed by 24 weeks of continuation chemotherapy (mercaptopurine, methotrexate) without radiotherapy
Number of subjects: 340
Study 9345074 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 weeks of continuation chemotherapy after 9 weeks of induction chemotherapy
Number of subjects: 340
Study 9345074 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 weeks of continuation chemotherapy with radiotherapy after 9 weeks of induction chemotherapy
Number of subjects: 340
Study 9345074 — intervention group
Group type: COMPARATOR
Intervention: No further therapy after 9 weeks of induction chemotherapy
Number of subjects: 340
Study 8403122 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified retrobulbar block (MRB)
Number of subjects: 150
Study 8403122 — intervention group
Group type: COMPARATOR
Intervention: Classical retrobulbar block (RB)
Number of subjects: 150
Study 8403122 — intervention group
Group type: COMPARATOR
Intervention: Peribulbar block (PB)
Number of subjects: 150
Study 2867316 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 min Apgar score less than or equal to 5
Number of subjects: 122
Study 2867316 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of moderate or severe encephalopathy
Number of subjects: 122
Study 29990565 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin (METV)
Number of subjects: 13
Study 29990565 — intervention group
Group type: EXPERIMENTAL
Intervention: Glibenclamide (METG)
Number of subjects: 13
Study 29990565 — intervention group
Group type: COMPARATOR
Intervention: Control (exercise session)
Number of subjects: 13
Study 27484339 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil infusion (0.1 μg/kg/min)
Number of subjects: 102
Study 27484339 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil infusion (0.1 μg/kg/min) + Alfentanil (5 μg/kg 10 min before end of surgery)
Number of subjects: 102
Study 27484339 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane alone
Number of subjects: 102
Study 24762066 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthracycline-based chemotherapy followed by taxane therapy (Arm A)
Number of subjects: 119
Study 24762066 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxane therapy followed by anthracycline-based chemotherapy (Arm B)
Number of subjects: 119
Study 24762066 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel chemotherapy
Number of subjects: 119
Study 24762066 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy sequence (Arm A vs Arm B)
Number of subjects: 119
Study 23174472 — intervention group
Group type: EXPERIMENTAL
Intervention: Travel by walking (TBW) before and after school
Number of subjects: 3076
Study 23174472 — intervention group
Group type: EXPERIMENTAL
Intervention: Consistent walkers (TBW in both sixth and eighth grades)
Number of subjects: 3076
Study 20205108 — intervention group
Group type: EXPERIMENTAL
Intervention: sulfonylurea
Number of subjects: 28
Study 20205108 — intervention group
Group type: EXPERIMENTAL
Intervention: sulfonylurea plus insulin
Number of subjects: 28
Study 20205108 — intervention group
Group type: EXPERIMENTAL
Intervention: routine diet and sulfonylurea therapy
Number of subjects: 28
Study 20205108 — intervention group
Group type: COMPARATOR
Intervention: baseline
Number of subjects: 28
Study 18580739 — intervention group
Group type: EXPERIMENTAL
Intervention: Back school program plus medication (n = 50)
Number of subjects: 102
Study 18580739 — intervention group
Group type: COMPARATOR
Intervention: Medication only (n = 52)
Number of subjects: 102
Study 16014852 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine (SP) and iron with folic acid supplementation
Number of subjects: 303
Study 16014852 — intervention group
Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine (SP) and iron without folic acid supplementation
Number of subjects: 303
Study 16014852 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplementation
Number of subjects: 303
Study 12185327 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen for 5 years
Number of subjects: 0
Study 12185327 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovarian ablation or suppression combined with tamoxifen
Number of subjects: 0
Study 10072410 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine (6.25 to 50 mg per day)
Number of subjects: 60
Study 10072410 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 10072410 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 60
Study 7793648 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg oral clonidine
Number of subjects: 8
Study 7793648 — intervention group
Group type: COMPARATOR
Intervention: 50 mg lidocaine
Number of subjects: 8
Study 1684743 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulindac
Number of subjects: 16
Study 1684743 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 16
Study 1684743 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 7041287 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline sulphate aerosol
Number of subjects: 26
Study 7041287 — intervention group
Group type: COMPARATOR
Intervention: Placebo aerosol
Number of subjects: 26
Study 30631933 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic removal of vagal nerve blocking device
Number of subjects: 30
Study 28113631 — intervention group
Group type: EXPERIMENTAL
Intervention: Human footstep sounds
Number of subjects: 0
Study 28113631 — intervention group
Group type: COMPARATOR
Intervention: Computer-generated sound
Number of subjects: 0
Study 28113631 — intervention group
Group type: EXPERIMENTAL
Intervention: Asynchronous auditory feedback
Number of subjects: 0
Study 28113631 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronous auditory feedback
Number of subjects: 0
Study 27578062 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused history in series choreography (after primary survey)
Number of subjects: 14
Study 27578062 — intervention group
Group type: COMPARATOR
Intervention: Focused history in parallel choreography (concurrent with primary survey)
Number of subjects: 14
Study 23371750 — intervention group
Group type: EXPERIMENTAL
Intervention: Right anodal/left cathodal stimulation
Number of subjects: 32
Study 23371750 — intervention group
Group type: EXPERIMENTAL
Intervention: Left anodal/right cathodal stimulation
Number of subjects: 32
Study 23371750 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 32
Study 20063407 — intervention group
Group type: EXPERIMENTAL
Intervention: LiquiPrep® (LP)
Number of subjects: 194
Study 20063407 — intervention group
Group type: COMPARATOR
Intervention: Papanicolaou (Pap) smear
Number of subjects: 194
Study 20009130 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-ribavirin treatment
Number of subjects: 44
Study 17972478 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory-encoding task
Number of subjects: 0
Study 17972478 — intervention group
Group type: COMPARATOR
Intervention: Search tasks (defined by category or exemplar)
Number of subjects: 0
Study 15058117 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 2 mg/kg with rocuronium 0.6 mg/kg
Number of subjects: 40
Study 15058117 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone 4 mg/kg with rocuronium 0.6 mg/kg
Number of subjects: 40
Study 11302283 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose diuretic (indapamide sustained release 1.5mg daily) and additional ACE inhibitor (perindopril) therapy if required
Number of subjects: 2100
Study 11302283 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2100
Study 9868810 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnosis with forced recall
Number of subjects: 300
Study 9868810 — intervention group
Group type: COMPARATOR
Intervention: Waking condition
Number of subjects: 300
Study 9868810 — intervention group
Group type: COMPARATOR
Intervention: Non-forced recall
Number of subjects: 300
Study 7979670 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (150 mg/day) for 7 days before operation
Number of subjects: 40
Study 7979670 — intervention group
Group type: COMPARATOR
Intervention: Control group (no coenzyme Q10)
Number of subjects: 40
Study 2659340 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracaine in 8% glucose
Number of subjects: 80
Study 2659340 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracaine in 5% glucose
Number of subjects: 80
Study 2659340 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine in 8% glucose
Number of subjects: 80
Study 2659340 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine in 5% glucose
Number of subjects: 80
Study 29875020 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 micrograms dexmedetomidine (BD group)
Number of subjects: 90
Study 29875020 — intervention group
Group type: COMPARATOR
Intervention: 25 micrograms fentanyl (BF group)
Number of subjects: 90
Study 29875020 — intervention group
Group type: COMPARATOR
Intervention: 0.5 ml normal saline (BN group)
Number of subjects: 90